Jeffrey A. Engelman

Cancer Research Center

Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index131
i10-index225
Publications876
Citations85,828

Grants

22 total · 0 active

NIH #2R01CA137008-06

Impact of heterogeneity on response to EGFR T790M inhibitors

Amount
$406K
Period
2009-03-012020-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5R01CA140594-06

Therapeutic strategies for specific subsets of KRAS mutant lung cancers

Amount
$497K
Period
2009-08-032018-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #2R01CA140594-05

Therapeutic strategies for specific subsets of KRAS mutant lung cancers

Amount
$531K
Period
2009-08-032018-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

22 total · 0 active

NIH #2R01CA137008-06

Impact of heterogeneity on response to EGFR T790M inhibitors

Amount
$406K
Period
2009-03-012020-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5R01CA140594-06

Therapeutic strategies for specific subsets of KRAS mutant lung cancers

Amount
$497K
Period
2009-08-032018-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #2R01CA140594-05

Therapeutic strategies for specific subsets of KRAS mutant lung cancers

Amount
$531K
Period
2009-08-032018-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA164273-03

Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors

Amount
$341K
Period
2012-02-202016-12-31
PIs
2
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5R01CA164273-02

Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors

Amount
$331K
Period
2012-02-202016-12-31
PIs
2
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #1R01CA164273-01

Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors

Amount
$353K
Period
2012-02-202016-12-31
PIs
2
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5R01CA140594-07

Therapeutic strategies for specific subsets of KRAS mutant lung cancers

Amount
$512K
Period
2009-08-032016-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA164273-04

Identification of Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors

Amount
$352K
Period
2012-02-202015-12-31
PIs
2
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5R01CA137008-05

The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted Therapies

Amount
$321K
Period
2009-03-012015-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5R01CA137008-04

The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted Therapies

Amount
$341K
Period
2009-03-012013-12-31
PIs
1
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5R01CA137008-03

The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted Therapies

Amount
$341K
Period
2009-03-012013-12-31
PIs
1
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5R01CA137008-02

The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted Therapies

Amount
$352K
Period
2009-03-012013-12-31
PIs
1
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #1R01CA137008-01

The Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted Therapies

Amount
$370K
Period
2009-03-012013-12-31
PIs
1
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #4R01CA140594-03

Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer

Amount
$497K
Period
2009-08-032013-06-30
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA140594-04

Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer

Amount
$496K
Period
2009-08-032013-03-31
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA140594-02

Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer

Amount
$476K
Period
2009-08-032011-06-30
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #1R01CA140594-01

Inhibition of P13k and MEK Pathways in the Treatment of Lung Cancer

Amount
$434K
Period
2009-08-032011-06-30
PIs
2
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5K08CA120060-05

Molecular mechanisms of PI3K activation in non-small cell lung cancer

Amount
$144K
Period
2006-04-052011-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5K08CA120060-04

Molecular mechanisms of PI3K activation in non-small cell lung cancer

Amount
$143K
Period
2006-04-052011-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5K08CA120060-03

Molecular mechanisms of PI3K activation in non-small cell lung cancer

Amount
$142K
Period
2006-04-052011-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #5K08CA120060-02

Molecular mechanisms of PI3K activation in non-small cell lung cancer

Amount
$141K
Period
2006-04-052011-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

NIH #1K08CA120060-01

Molecular mechanisms of PI3K activation in non-small cell lung cancer

Amount
$140K
Period
2006-04-052011-03-31
PIs
1
Est. capacity / PI
~0 students

Awarded at MASSACHUSETTS GENERAL HOSPITAL

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 45
Open author page on OpenAlex →